Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ASSEMBLY BIOSCIENCES, INC.v302239_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 13, 2012

 

  VENTRUS BIOSCIENCES, INC.  
  (Exact name of registrant as specified in its charter)  

 

 

Delaware 001-35005 20-8729264
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer ID Number)
     
99 Hudson Street, 5th Floor, New York, New York   10013
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (646) 706-5208

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Ventrus Biosciences, Inc. will present at BIO CEO on February 13, 2012 and which is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits  
     
  Exhibit No. Description
     
  99.1 Slide presentation of February 13, 2012 to be presented at BIO CEO.

 

 
 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

    VENTRUS BIOSCIENCES, INC.  
       
       
       
Date:  February 13, 2012   /s/ David J. Barrett  
    David J. Barrett, Chief Financial Officer